Wockhardt Limited Market Cap ($3.38 Billion)
Market Cap & Net Worth: Wockhardt Limited (WOCKPHARMA)
Wockhardt Limited market cap. Wockhardt Limited (NSE:WOCKPHARMA) has a market capitalization of $3.38 Billion (Rs312.46 Billion) as of October 31, 2026. Listed on the NSE stock exchange, this India-based company holds position #4457 globally and #196 in its home market, demonstrating a 2.43% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Wockhardt Limited's stock price Rs1922.90 by its total outstanding shares 162492169 (162.49 Million).
Wockhardt Limited Market Cap History (2015–2026)
Wockhardt Limited market cap history from 2015 to 2026. Data shows growth from $2.44 Billion to $3.38 Billion (2.71% CAGR). Check Wockhardt Limited (WOCKPHARMA) stock price for real-time trading data and today's change.
Index Memberships
Wockhardt Limited is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NIFTY MICROCAP 250
NIFTYMICROCAP250
|
$143.20 Billion | 2.36% | #2 of 250 |
|
NIFTY TOTAL MARKET
NIFTYTOTALMKT
|
$3.04 Trillion | 0.11% | #177 of 750 |
Weight: Wockhardt Limited's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Wockhardt Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Wockhardt Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see WOCKPHARMA cash flow metrics for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
0.08x
Wockhardt Limited's market cap is 0.08 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.07 Billion | $44.53 Billion | $2.51 Billion | 0.02x | 0.42x |
| 2017 | $1.51 Billion | $39.66 Billion | -$1.96 Billion | 0.04x | N/A |
| 2018 | $847.63 Million | $39.24 Billion | -$6.08 Billion | 0.02x | N/A |
| 2019 | $378.98 Million | $35.66 Billion | -$1.95 Billion | 0.01x | N/A |
| 2020 | $885.38 Million | $28.44 Billion | -$692.20 Million | 0.03x | N/A |
| 2021 | $668.79 Million | $27.08 Billion | $6.86 Billion | 0.02x | 0.10x |
| 2022 | $391.96 Million | $32.30 Billion | -$2.44 Billion | 0.01x | N/A |
| 2023 | $745.71 Million | $26.57 Billion | -$5.59 Billion | 0.03x | N/A |
| 2024 | $2.49 Billion | $28.30 Billion | -$4.63 Billion | 0.09x | N/A |
| 2025 | $2.54 Billion | $30.35 Billion | -$470.00 Million | 0.08x | N/A |
Competitor Companies of WOCKPHARMA by Market Capitalization
Companies near Wockhardt Limited in the global market cap rankings as of October 31, 2026. See Wockhardt Limited balance sheet quality to understand what proportion of total assets are financed by equity.
Key companies related to Wockhardt Limited by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #515 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #536 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #600 globally with a market cap of $45.38 Billion USD ( CN¥310.15 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #626 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #515 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #536 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $45.98 |
| #600 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.38 Billion | CN¥48.62 |
| #626 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €17.90 |
Market Capitalization of Wockhardt Limited (2015–2026)
Market capitalization of Wockhardt Limited from 2015 to today. Between 2015 and today, Wockhardt Limited's market cap moved from $2.44 Billion to $ 3.38 Billion, with a yearly change of 2.71%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Rs3.38 Billion | +32.96% |
| 2025 | Rs2.54 Billion | +2.07% |
| 2024 | Rs2.49 Billion | +233.89% |
| 2023 | Rs745.71 Million | +90.25% |
| 2022 | Rs391.96 Million | -41.39% |
| 2021 | Rs668.79 Million | -24.46% |
| 2020 | Rs885.38 Million | +133.62% |
| 2019 | Rs378.98 Million | -55.29% |
| 2018 | Rs847.63 Million | -43.82% |
| 2017 | Rs1.51 Billion | +41.60% |
| 2016 | Rs1.07 Billion | -56.38% |
| 2015 | Rs2.44 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 30th, 2026 the market cap of Wockhardt Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.38 Billion USD |
| MoneyControl | $3.38 Billion USD |
| MarketWatch | $3.38 Billion USD |
| marketcap.company | $3.38 Billion USD |
| Reuters | $3.38 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Wockhardt Limited
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH… Read more